DarioHealth (NASDAQ:DRIO) Coverage Initiated by Analysts at Litchfield Hills Research

Equities research analysts at Litchfield Hills Research assumed coverage on shares of DarioHealth (NASDAQ:DRIOGet Free Report) in a research report issued on Monday,Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Litchfield Hills Research’s price target suggests a potential upside of 351.81% from the company’s previous close.

Several other analysts have also commented on DRIO. Stifel Nicolaus dropped their price target on shares of DarioHealth from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. TD Cowen downgraded shares of DarioHealth from a “buy” rating to a “hold” rating and reduced their target price for the stock from $2.00 to $1.00 in a research note on Wednesday, January 29th.

Read Our Latest Report on DarioHealth

DarioHealth Price Performance

DRIO stock traded up $0.00 during mid-day trading on Monday, hitting $0.66. The company had a trading volume of 23,546 shares, compared to its average volume of 278,992. DarioHealth has a 12-month low of $0.50 and a 12-month high of $1.91. The company has a market capitalization of $29.18 million, a price-to-earnings ratio of -0.70 and a beta of 1.55. The company has a 50-day moving average price of $0.68 and a 200 day moving average price of $0.73. The company has a quick ratio of 1.32, a current ratio of 1.57 and a debt-to-equity ratio of 0.35.

DarioHealth (NASDAQ:DRIOGet Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). DarioHealth had a negative net margin of 205.62% and a negative return on equity of 72.16%. The company had revenue of $6.75 million during the quarter, compared to analysts’ expectations of $7.48 million. During the same period last year, the firm earned $0.05 earnings per share. On average, research analysts anticipate that DarioHealth will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On DarioHealth

A hedge fund recently bought a new stake in DarioHealth stock. AMH Equity Ltd acquired a new position in shares of DarioHealth Corp. (NASDAQ:DRIOFree Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 250,000 shares of the company’s stock, valued at approximately $153,000. AMH Equity Ltd owned 0.60% of DarioHealth at the end of the most recent reporting period. 33.39% of the stock is currently owned by institutional investors.

DarioHealth Company Profile

(Get Free Report)

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Read More

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.